President, CEO and Chairman of the Board
Lance Alstodt has been appointed the Company’s President, Chief Executive Officer and
Chairman of the Board as of Nov 16, 2020. Mr. Alstodt brings over 25 years of experience in
leading medical technology and lifesciences companies in operations, capital raising activities, strategy, and mergers and acquisitions.
Most recently, Mr. Alstodt was the Founder and CEO of MedVest Consulting Corporation
(“MedVest”), an advisory and capital firm focused exclusively within the healthcare sector,
focusing on growth and channel strategy, strategic planning, merger and acquisition support and investor activities.
Prior to MedVest, Mr. Alstodt was a career investment banker with over 25 years of experience in healthcare investment banking, including mergers and acquisitions. In 2011, Mr. Alstodt joined Leerink Partners as Managing Director to help lead its medical technology sector. Mr. Alstodt brings significant domain experience within the orthopedic and spine specific sectors.
From 2008-2011, Mr. Alstodt was a Managing Director and Head of Medical Technology at
Oppenheimer & Co. From 2000-2008, he was a Managing Director in the Healthcare Group and Global M&A Group at Bank of America Merrill Lynch (“BAML”). Prior to BAML, Mr. Alstodt spent seven years in the Global M&A Group at J.P. Morgan Chase, where he worked extensively on acquisitions, leveraged buyouts, private and public financings, exclusive sales and general advisory assignments.
Mr. Alstodt received a B.A. in Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing.
Chief Scientist & VP, R&D
Francisco Silva joined BRT in April 2011 and is Vice President of Research and Development. Mr. Silva is responsible for all laboratory operations and is involved in the development and growth of our stem cell programs.
Mr. Silva previously served as Chief Executive Officer of two companies engaged in the
commercialization of human-based biologics for both research and therapeutic applications.
From 2003 to 2007, Mr. Silva was Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell-based platforms. He was responsible for the development of experimental designs that focused on germ line
reprogramming stem cell platforms.
Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research
Mr. Silva graduated from California State Polytechnic University with a degree in Biology.He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.